The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends
Tarsus Pharmaceuticals selected the pharmacies in its XDEMVY limited distribution network to ensure patient access
Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, recently announced it was selected as a limited distribution partner for VYVGART
The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for voxelotor (Oxbryta®) for the treatment of sickle cell disease in patients aged 4 to 11 years
The FDA approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy
The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)
Large insurers are implementing policies requiring health care providers to get provider-administered therapies from specialty pharmacies